Rocket Lab's Stock-Market Feedback Loop: When Deal Mechanics Trump Fundamentals

Rocket Lab's stock falls 19% in 7 sessions as Iridium deal's variable exchange ratio amplifies regulatory noise, despite record revenue and backlog.

There is a peculiar moment in a growth company's life when the share price stops tracking the business and starts tracking the deal. Rocket Lab appears to be living through exactly that phase right now. The company's operations are humming — record revenue, a swelling backlog, and a fresh commercial win for its next-generation rocket — yet the stock has spent seven consecutive sessions sliding, shedding roughly 19.4 percent and, by some estimates, around $10 billion in market value.

The disconnect is striking. On Friday alone, shares fell another 4.1 percent, bringing the weekly decline to 11 percent. The stock now sits about 18 percent below its 50-day moving average and 58 percent beneath the 52-week high of $133.80 reached in May. A casual observer might conclude the company is in trouble. The more accurate reading is that a structural feature of the $8 billion Iridium Communications acquisition is amplifying regulatory noise into outsized price moves.

The Collar That Bites Back

The immediate trigger for the latest leg lower was not an earnings warning but a regulatory filing. SpaceX has lodged a complaint with the US Federal Communications Commission regarding Iridium, raising questions about potential spectrum interference from future Starlink gateways. Crucially, SpaceX is not opposing the Rocket Lab-Iridium combination itself — it is asking for closer scrutiny during the license-transfer review. That distinction did little to calm investors, and the stock dropped around 6 percent on the news.

The outsized reaction stems from how the deal is structured. Each Iridium share is to be exchanged for $27 in cash plus a variable number of Rocket Lab shares, calculated using the ten-day volume-weighted average price shortly before closing. The arithmetic is unforgiving: when Rocket Lab's stock falls, the exchange ratio shifts automatically, meaning any negative headline becomes a self-reinforcing pressure on the transaction terms. Market observers suggest relatively few investors have fully internalized this mechanism — which is precisely why the sell-off has felt so mechanical.

The regulatory calendar now looms large. The waiting period under US antitrust law expired on August 12, SEC registration documents have been filed, and FCC applications for the Iridium license transfers have been pending since August 10. Iridium shareholders are scheduled to vote on the merger on September 24. Between now and then, every piece of market-moving news carries the potential to alter the deal's economics.

Neutron's First Customer Arrives — With a Caveat

Amid the regulatory turbulence, Rocket Lab delivered a meaningful commercial milestone over the weekend: Kepler Communications has signed the first dedicated launch contract for the Neutron rocket, with a mission tentatively targeted for no earlier than 2028. The agreement signals that the medium-lift vehicle is attracting demand beyond Rocket Lab's own constellation ambitions.

Yet the timing of Neutron's debut flight remains a source of investor anxiety. The company indicated on Thursday that the 2026 launch window is "narrowing," prompting speculation among market watchers that the first flight could slip into 2027. For a company whose valuation leans heavily on future Neutron revenue, that ambiguity is a thread investors are pulling on.

The Operational Picture Tells a Different Story

Strip away the deal-related noise, and Rocket Lab's underlying business looks robust. Second-quarter revenue came in at $234.07 million, beating the $231.62 million consensus, while the backlog expanded to $2.36 billion — more than double the year-earlier figure. The company has guided to third-quarter revenue between $250 million and $265 million, with GAAP gross margin of 29 to 31 percent. The GAAP loss per share of $0.08 was wider than the $0.06 analysts had expected, though that blemish did little to dent the broader narrative.

August was a busy month on the contract front. The US Space Force awarded a $12 million contract for secure optical communications in orbit, added Rocket Lab to the multi-billion-dollar NITE-STAR framework, and separately handed over a $397 million satellite order under a target-tracking program. Viasat selected Rocket Lab to build a GEO satellite bus for a military program, and the company launched the first batch of eight satellite platforms for MDA Space under a $143 million contract. The 93rd Electron mission lifted off from New Zealand on August 20.

Roth Capital responded to the quarterly numbers in early August by setting a price target of $110.00.

Insider Sales: A Footnote, Not a Signal

Several executives, including General Counsel Arjun Kampani and Chief Operating Officer Frank Klein, sold shares in August under pre-arranged trading plans, largely to cover tax obligations tied to equity compensation. The managers retained the bulk of their holdings after the sales — a detail that suggests the transactions reflect routine portfolio management rather than wavering confidence.

The Bigger Lesson

What makes this episode instructive beyond Rocket Lab's own story is what it says about modern deal-making. As billion-dollar acquisitions increasingly incorporate variable stock components, the acquirer's share price becomes a playing field for competitors and regulators alike. A well-timed filing by a rival can, through the mechanics of the exchange ratio, influence the ultimate price paid — without any direct challenge to the deal itself.

That is not a sign of corporate weakness. It is a structural feature of contemporary merger financing that investors are still learning to price in. For Rocket Lab shareholders, the calculus is straightforward: the business is delivering, but until the Iridium vote on September 24, the stock will remain hostage to a feedback loop that has little to do with launch cadence or backlog growth.